Luye Pharma Group
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Luye Pharma Group sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Luye Pharma Group: 22 sponsored US clinical trials, none currently recruiting.
Luye Pharma Group sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 21 completed. 1 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 3 trials.
Top-decile sponsor footprint
Luye Pharma Group ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Comparative Efficacy, Safety, PK, and Immunogenicity Study
NCT05853354
A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects
NCT07671833
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
NCT05321602
Relative Bioavailability of LY03010 Compared to Listed Drug
NCT04922593
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
NCT04384666
Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients
NCT04572685
A Relative Bioavailability Food Effect Study of LY03005
NCT03822065
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
NCT03751488
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
NCT03733561
A Study of LY03005 vs Pristiq
NCT03733574
Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
NCT03589066
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
NCT03450109
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
NCT03357796
Pilot BA Study of New LY03005 vs Pristiq
NCT02988024
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
NCT02728947
Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers
NCT02603770
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
NCT02271412
Bioavailability of LY03004 and Risperdal® Consta®
NCT02091388
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
NCT02186769
Safety, Tolerability and Pharmacokinetics Study of LY03005
NCT02055300
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
NCT02055274
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
NCT02055287
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 3 | 1 |
How the Luye Pharma Group early-phase archive is shaped
22 indexed studies, none listed as recruiting (0% open); 21 completed (95%).
Phase mix: 1 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Luye Pharma Group: archived-pipeline peers nationwide
Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Luye Pharma Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 archived trials
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Luye Pharma Group page
22 registered trials is a research-attention snapshot, not an endorsement of Luye Pharma Group or any single study.
- None of Luye Pharma Group's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Schizophrenia is the condition Luye Pharma Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Luye Pharma Group pipeline card: 22 registered trials from official public datasets.Report a data error.